Extended Data Fig. 5: The effect of senolytics combined with αPD-1 on TIME of 4-NQO mice.
From: Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results
a, Representative images of tongue sections from mice, fed with 4-nitroquinoline-1-oxide (4-NQO)-containing drinking water for 12, 20, and 28 weeks, stained with hematoxylin and eosin (HE). Scale bar, 50μm. n = 3 mice per timepoint. For each mouse, 5 random fields of view (FOV) were imaged from distinct tissue sections. b, Images of tongue of mice after receiving Isotype, αPD-1, αPD-1 + CP or αPD-1 + DQ treatment (n = 6 each group). Red arrows indicate tumor-like nodules. c, Line graph illustrating the change in mouse body weight over time after receiving Isotype, αPD-1, αPD-1 + CP or αPD-1 + DQ treatment (n = 6 per group). d, Flow cytometry gating strategy for assessing the proportions of CD4+, CD8+, as well as T cell subtypes. e-g, Flow cytometry immunophenotyping of splenic cells, bone marrow Cells and blood showing the frequencies of CD4+, CD8+ and B220+ cells in mice after receiving Isotype, αPD-1, αPD-1 + CP or αPD-1 + DQ treatment (n = 6 each group). h, Senescence markers p16 and p21 expression in CD8+ TILs from the mice treated with Isotype, αPD-1, αPD-1 + CP or αPD-1 + DQ (n = 6 per group).
